(UMRX) – Press Releases
-
Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference
-
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress
-
SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics
-
Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO
-
SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics
-
Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
-
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
-
Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates
-
Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates
-
Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital
-
Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers
-
Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers
-
Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting
-
Unum Therapeutics to Present at Upcoming Investor Conference
-
Unum Therapeutics Reports Third Quarter 2019 Financial Results
-
Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Unum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers
-
Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting
-
Unum Therapeutics to Present at Upcoming Industry Conferences in September
-
Unum Therapeutics to Present at Upcoming September Investor Conferences
-
Unum Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Updates
-
Unum Therapeutics to Review Second Quarter 2019 Financial Results on August 12, 2019
-
Unum Therapeutics Announces New Appointments to its Board of Directors
-
Unum Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
-
Unum Therapeutics Announces Regulatory Update from Phase 1 Trial with ACTR087
-
Unum Therapeutics Strengthens and Expands Leadership Team
-
Unum Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
-
Unum Therapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 13, 2019 at 8:00 A.M. ET
-
Unum Therapeutics to Present at Two Upcoming Investor Conferences
-
Unum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
-
Unum Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on March 28, 2019 at 8:00 A.M. ET
-
Unum Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference 2019
-
Rob Perez Joins General Atlantic as Operating Partner to Bolster Life Sciences Practice
-
CORRECTING and REPLACING -- Unum Therapeutics Announces 2019 Goals and Expected Milestones
-
Unum Therapeutics Announces 2019 Goals and Expected Milestones
-
Unum Therapeutics Announces Transition of Chief Financial Officer
-
Unum Therapeutics Added to NASDAQ Biotechnology Index
-
Unum Therapeutics Announces US Patent Protection for ACTR Technology
-
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-20-03 at the 2018 ASH Annual Meeting
-
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-17-01 at the 2018 ASH Annual Meeting
-
CORRECTION: Unum Therapeutics to Host Investor Event on its Efforts to Realize the Promise of T Cell Therapies in Solid Tumors
-
Unum Therapeutics to Host Investor Event on its Efforts to Realize the Promise of T Cell Therapies in Solid Tumors
-
Unum Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
-
Unum Therapeutics to Present Preclinical Data on Applications of ACTR Proprietary Technology Platform in Solid Tumors at the San Antonio Breast Cancer Symposium
-
Unum Therapeutics to Present Preclinical Data on a New, Emerging Platform Technology for Solid Tumors at the SITC Annual Meeting
-
Unum Therapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 12, 2018 at 4:30 P.M. ET
-
Unum Therapeutics to Present Preliminary Results from Ongoing Phase 1 Studies ATTCK-20-03 and ATTCK-17-01 at the 2018 ASH Annual Meeting
-
Unum Therapeutics Announces Abstract Accepted for Presentation at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
-
Unum Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference
-
Unum Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
Back to UMRX Stock Lookup